LENZ Therapeutics (LENZ) Enterprise Value (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Enterprise Value of -$258.4 million for Q1 2026, down 1015.84% year-over-year from $28.2 million in Q1 2025, and up 11.62% quarter-over-quarter from -$292.3 million in Q4 2025.
LENZ Therapeutics (LENZ) Enterprise Value (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Enterprise Value for 7 consecutive years, with -$258.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 1015.84% year-over-year to -$258.4 million; the TTM figure through Mar 2026 stood at -$258.4 million (down 1015.84% YoY), while the FY2025 annual figure was -$292.3 million, down 1342.12% from the prior year.
- Enterprise Value advanced to -$258.4 million in Q1 2026 per LENZ's latest filing, from -$292.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$20.3 million in Q4 2024 and bottomed at -$339.2 million in Q1 2022.
- Historically, Enterprise Value has averaged -$181.3 million across 5 years, with a median of -$202.2 million in 2023.
- On a YoY basis, Enterprise Value climbed as much as 88.45% in 2025 and fell as far as 1342.12% in 2025.
- LENZ Therapeutics' Enterprise Value stood at -$220.5 million in 2022, then surged by 70.16% to -$65.8 million in 2023, then surged by 69.19% to -$20.3 million in 2024, then sank by 1342.12% to -$292.3 million in 2025, then gained by 11.62% to -$258.4 million in 2026.
- Business Quant data shows LENZ's Enterprise Value at -$258.4 million in Q1 2026, -$292.3 million in Q4 2025, and -$202.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | -220.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -220.00 Mn |
| Mar 31, 2026 | -258.39 Mn |
| Dec 31, 2025 | -292.35 Mn |
| Sep 30, 2025 | -202.17 Mn |
| Jun 30, 2025 | -37.71 Mn |
| Mar 31, 2025 | -23.16 Mn |
| Dec 31, 2024 | -20.27 Mn |
| Sep 30, 2024 | -41.15 Mn |
| Jun 30, 2024 | -84.14 Mn |
| Mar 31, 2024 | -200.46 Mn |
| Dec 31, 2023 | -65.79 Mn |
| Sep 30, 2023 | -233.99 Mn |
| Jun 30, 2023 | -246.67 Mn |
| Mar 31, 2023 | -202.25 Mn |
| Dec 31, 2022 | -220.50 Mn |
| Sep 30, 2022 | -291.69 Mn |
| Jun 30, 2022 | -322.29 Mn |
| Mar 31, 2022 | -339.18 Mn |
| Dec 31, 2021 | -376.98 Mn |
| Sep 30, 2021 | -394.95 Mn |